Baohong Yang*1, Aiying Qin†1, Kongyuan Zhang‡, Haipeng Ren*, Shuzhen Liu*, Xiaolei Liu§, Xiangpo Pan¶, Guohua Yu*
Oncology Research, Vol.25, No.9, pp. 1601-1606, 2017, DOI:10.3727/096504017X14928634401178
Abstract Epithelial growth factor receptor (EGFR) mutations are present in 10%–26% of non-small cell lung cancer
(NSCLC) tumors and are associated with the response to tyrosine kinase inhibitors (TKIs). This study aimed to
detect and quantify the presence of circulating tumor cells (CTCs) in EGFR-mutant NSCLC patients and investigate their possible role in providing prognostic information. Enrolled patients received erlotinib (150 mg)
or gefitinib (250 mg) orally once daily as the first-line treatment. Serial blood samples were taken at baseline
(CTC-d0) and on day 28 (CTC-d28) following the initiation of erlotinib/gefitinib for detection of CTCs using… More >
Login
Register
